Spero Therapeutics Inc at H.C. Wainwright BioConnect Investor Conference Transcript
Thank you so much for joining us for the next in our series of corporate presentations here at the H.C. Wainwright BioConnect Conference. My name is Ram Selvaraju. I'm the Managing Director and senior healthcare equity research analyst here at the firm.
It's my pleasure to introduce the next presenting company, which is Spero Therapeutics. Currently traded on the Nasdaq under the ticker symbol SPRO. We cover Spero Therapeutics with a buy rating. This is a company doing next-generation therapeutics development work in the anti-infective space.
Presenting for the company will be Sath Shukla, Chief Financial Officer. Sir, over to you.
Thanks, Ram, for that introduction. And Thanks to HCW for having us here today.
So as Spero Therapeutics enters its first decade as a company, we are a leader in the infectious and rare disease space. The company has three late-stage medicines targeting indications with high unmet need and strong
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
